Connolly 1995.

Methods	Setting: multicentre study UK, primary care Design: parallel group Length of intervention period: 8 weeks Randomisation: yes, method not stated Allocation concealment: unclear Masking: open, no blinding Excluded: stated Withdrawals: stated Baseline characteristics: comparable Jadad score: 2
Participants	283 adults enrolled, 190 randomised: 43M 39F Age range: 18‐70 years Inclusion criteria: Adult asthmatic patients Receiving BDP or BUD 200 mcg/d or less During 2 week run‐in period: Symptom score 1 or greater on 10 successive days FEV1 > 50 (% predicted) Able to use delivery devices Exclusion criteria: Current treatment with OCS or > 6 courses in last year Change in asthma therapy in last 6 weeks Serious coexistent illness
Interventions	FP: 100 mcg 1 actuation 2xdaily (200 mcg/d) via Diskhaler DPI BUD: 200 mcg 1 actuation 2xdaily (400 mcg/d)via Tubuhaler DPI
Outcomes	Change in morning PEFR compared to baseline Change in diurnal variation in PEFR compared to baseline % symptom free days % symptom free nights % rescue beta2 agonist free days % rescue beta2 agonist free nights Physician assessed level of overall asthma control Patient assessed level of overall asthma control Morning plasma cortisol
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Described as randomised; other information not available
Allocation concealment?	Unclear risk	Information not available
Blinding? All outcomes	High risk	Open label